Deferasirox and Rosiglitazone

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Deferasirox may increase the blood levels of rosiglitazone. You may be more likely to experience side effects such as hypoglycemia, or low blood sugar, that can sometimes occur with the use of rosiglitazone. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, weakness, tremor, nausea, hunger, sweating, and palpitation. The risk of other serious but uncommon side effects such as fluid retention, macular edema (swelling in the back of the eye), new or worsening heart failure, heart attack, bone fractures, anemia, and liver problems may also be increased. You may need a dose adjustment or more frequent monitoring of your blood sugar and other tests to safely use both medications. Contact your doctor immediately if you experience sudden lightheadedness; nausea or vomiting; blurred vision or other visual abnormalities; excessive or rapid weight gain; swelling in the ankles or legs; shortness of breath or difficulty breathing; unusual tiredness; chest pain or tightness; or pain in the arms, back, neck, jaw or stomach. You should also seek prompt medical attention if you develop signs and symptoms of liver damage such as fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and yellowing of the skin or eyes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with inhibitors of CYP450 2C8 may increase the plasma concentrations of rosiglitazone, which is primarily metabolized by the isoenzyme. In 10 healthy volunteers given the potent CYP450 2C8 inhibitor gemfibrozil (600 mg twice daily) for two days prior to coadministration with a single 4 mg dose of rosiglitazone on day 3, mean rosiglitazone systemic exposure (AUC) increased by 127% and elimination half-life from 3.6 to 7.6 hours, while the plasma concentration measured 24 hours after dosing increased by 9.8-fold. In 10 healthy volunteers given the less potent CYP450 2C8 inhibitor trimethoprim (160 mg orally twice a day) for 4 days prior to coadministration with a single 4 mg dose of rosiglitazone, mean AUC of rosiglitazone increased by 37% and half-life from 3.8 to 4.8 hours. Nearly identical results were reported in eight healthy volunteers in another study administered trimethoprim and rosiglitazone.

MANAGEMENT: Given the potential for dose-related adverse events with rosiglitazone, caution is advised during coadministration with CYP450 2C8 inhibitors, particularly in patients already receiving a higher dosage of rosiglitazone (e.g., 8 mg/day). Close monitoring for the development of hypoglycemia and other adverse effects is recommended, such as fluid retention; weight gain; new or worsening heart failure; pulmonary, peripheral, and macular edema; angina; bone fractures; anemia; and liver enzyme elevations. Patients should regularly monitor their blood sugar and learn how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation. The dosage of rosiglitazone may require adjustment if an interaction is suspected. Likewise, patients should be observed for potential loss of glycemic control following discontinuation of the CYP450 2C8 inhibitor, and the rosiglitazone dosage adjusted as necessary.

Deferasirox

Generic Name: deferasirox

Brand name: Exjade, Jadenu, Jadenu Sprinkle

Synonyms: n.a.

What is Deferasirox?

Rosiglitazone

Generic Name: rosiglitazone

Brand name: Avandia

Synonyms: n.a.

What is Rosiglitazone?